Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621696 · ClinicalTrials.gov registry record · Phase 2
Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"
A Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma, sponsored by Washington University School of Medicine.
- Active
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
- 1
- Study location
NCT03621696 is a Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 63 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03621696, a Phase 2 study of HPV Related Oropharyngeal Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by Washington University School of Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.
Conditions Studied
Interventions
- DRUG Cisplatin
- PROCEDURE Surgery
- RADIATION Intensity modulated radiation therapy
- RADIATION Intensity modulated proton therapy
- OTHER FACT-H&N
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2026-03-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03621696
The ClinicalTrials.gov registry entry for NCT03621696 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HPV Related Oropharyngeal Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT03621696 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.
Frequently Asked Questions
What is clinical trial NCT03621696 about?
NCT03621696 is a clinical study titled "Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"". The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.
What is the current status of trial NCT03621696?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2018-10-23. Estimated completion is 2026-03-10.
What conditions does trial NCT03621696 study?
This clinical trial studies the following conditions: HPV Related Oropharyngeal Squamous Cell Carcinoma.
What interventions are being tested in trial NCT03621696?
The interventions under investigation include: Cisplatin (DRUG), Surgery (PROCEDURE), Intensity modulated radiation therapy (RADIATION), Intensity modulated proton therapy (RADIATION), FACT-H&N (OTHER).
Who is sponsoring clinical trial NCT03621696?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03621696 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.